Market Research Future (MRFR) has published on the “global Epigenetics Drugs and Diagnostic Technologies Market”.
Market Research Future (MRFR) has published a cooked research report on the “global epigenetics drugs and diagnostic technologies market” that contains the information from 2019 to 2032. The epigenetics drugs and diagnostic technologies market is accounted to register a CAGR of 21.90% during the forecast period of 2023 to 2032.
MRFR recognizes the following companies as the key players in the global epigenetics drugs and diagnostic technologies market— Hologic, Inc. (US), Gilead Sciences, Inc. (US), Celleron Therapeutics (US), Illumina, Inc. (US), AstraZeneca PLC (UK), LISEN lmprinting Diagnostics (US), Salarius Pharmaceuticals, Inc. (US), Jubilant Therapeutics (US), Oryzon Genomics (Spain), Epiaxis Therapeutics (Australia), and others.
The global epigenetics drugs and diagnostic technologies market is estimated to register a CAGR of 21.90% during the forecast period and is projected to reach USD 48.91 billion by 2032.
Epigenetics is currently in trend as it is widely utilized to detect cancer early and can identify which type of cancer a person has. Moreover, these drugs are responsible for tumor suppressor gene reactivation. There are several factors, such as rising incidences of chronic diseases such as oncology and the central nervous system (CNS), a rising number of approvals of epigenetic drugs for cancer, and an increasing number of product launches and pipeline launches, that positively contribute to the growth of the epigenetic drugs & diagnostic technologies market.
Additionally, as per the World Health Organization, the future trend for cancer is that there were 20 million new patients diagnosed with cancer in 2020, and it has been estimated that the cancer burden will increase by up to 60% globally in the next two decades. Moreover, it has been predicted that the global burden will increase by up to 30 million new cases by 2040. Furthermore, according to the World Social Report 2023, there were 761 million people aged 65 or older living in 2021, a number predicted to increase to 1.6 million by 2050. Hence, the above-mentioned statement shows that during the forecast year, cancer patients and the geriatric population will create flourishing opportunities.
However, the epigenetics side-effects in certain diseases such as heart diseases, neurological, cognitive disorder, and sexual dysfunction is restraining the global epigenetics drugs & diagnostic technologies market.
The global epigenetics drugs and diagnostic technologies market has been segmented based on drug type, diagnostic technologies, application, and end user.
On the basis of drug type, the market is segmented into DNA methyltransferases (DNMTs) inhibitors, histone deacetylases (HDACs) inhibitors, histone methyltransferase (HMT) inhibitors, and others. The DNA methyltransferases (DNMTs) inhibitors segment is further segmented into azacitidine, decitabine, and others and histone deacetylases (HDACs) inhibitors are further segmented into vorinostat, romidepsin, and others. The DNA methyltransferases (DNMTs) inhibitors segment held the largest market in 2022. The DNMTs inhibitor majorly utilize to treat acute myeloid leukemia (AML), chronic myeloid leukemia (CML) myelodysplastic syndromes (MDS) and approved drugs are available in the market which is burgeoning the growth of the segment.
Based on diagnostic technologies, the global epigenetics drugs and diagnostic technologies market has been segmented into DNA methylation and histone modification analysis, and others. The DNA methylation segment dominated the market in 2022, and histone modification analysis is projected to be the fastest-growing segment during the forecast period. DNA methylation has wide application to treat diseases such as cardiovascular, metabolic, neurological, and cancer diseases. The increasing prevalence of metabolic diseases namely stroke, and type II diabetes are propelling the segment’s growth. According to the World Stroke Organization, approximately 63% of the population has experienced a stroke which was lower percentage than the 70-year-old population in 2019, globally.
The global epigenetics drugs and diagnostic technologies market has been segmented based on application into oncology, neurology, autoimmune diseases, and others. The oncology segment dominated market growth in 2022, and neurology is projected to be the fastest-growing segment. The factors positively contributing to the segment's growth are the surge in cancer cases worldwide and rising incidences of neurology diseases, including brain tumours. According to the International Agency for Research on Cancer, the prevalence of brain cancer was 308,102 in 2020, in which Asia accounted for the largest prevalence share, followed by Europe, North America, Latin America and the Caribbean (LAC), and Africa.
Based on end user, the global epigenetics drugs and diagnostic technologies market has been segmented into hospitals & clinics, diagnostic centers, and others. The hospitals & clinics segment accounted for the largest share during the forecast period owing to high incidences of chronic diseases, namely cancer and neurology. Moreover, diagnostic centres are estimated to be the fastest-growing segment due to the high adoption of epigenetic instruments for early detection of diseases, including cancer.
The global epigenetics drugs and diagnostic technologies market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe epigenetics drugs and diagnostic technologies market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The epigenetics drugs and diagnostic technologies market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World epigenetics drugs and diagnostic technologies market comprises of Middle East, Africa, and Latin America.
The North America epigenetics drugs and diagnostic technologies market held the largest market share in 2022 due to factors such as the increasing prevalence of chronic diseases, including cancer, diabetes, and heart diseases, and the presence of major players such as Hologic, Inc. (US) and Gilead Sciences, Inc. (US). According to the American Society of Clinical Oncology (ASCO), there are 24,810 adults diagnosed with brain and spinal cord cancer in the US, of which the male ratio is higher than the female ratio. Furthermore, rapid adoption of epigenetic diagnostic technologies in hospitals & clinics and rising awareness of epigenetic drugs to treat diseases are bolstering the region’s market growth.
Furthermore, the Europe epigenetics drugs and diagnostic technologies market shows significant growth during the forecast period. This is due to the high adoption of technology-based epigenetics in diagnostic centers and the increasing incidence of neurological diseases. Moreover, the increasing number of clinical trials in Europe is burgeoning the market growth. For instance, in March 2023, Oryzon Genomics, S.A. (Spain), announced a selective histone deacetylase 6 (HDAC-6) inhibitor as a clinical development candidate for the treatment of neurological diseases such as charcot-marie-tooth (CMT), amyotrophic lateral sclerosis (ALS), and others.
Moreover, the Asia-Pacific epigenetics drugs and diagnostic technologies market growth is attributable to drivers such as the increasing prevalence of chronic diseases and the growing geriatric population. As per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022. Moreover, the older population will reach up to 1.3 billion people by 2050. Thus, the surge in the geriatric population in the Asia-Pacific region will increase the demand for epigenetic diagnostic devices in the region.
Additionally, the Middle East, Africa, and Latin America regions comprised the rest of the world. The region accounted for the lowest market share in the epigenetics drugs and diagnostic technologies market due to a lack of awareness associated with advanced epigenetic diagnostics. However, there is a surge in genetic diseases in Latin America, the Middle East, and Africa which is fueling the region’s market growth.
Key Findings of the Study